DOCSLIB.ORG

Dysregulation at Multiple Points of the Kynurenine Pathway Is a Ubiquitous Feature of Renal Cancer: Implications for Tumour Immune Evasion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dysregulation at Multiple Points of the Kynurenine Pathway Is a Ubiquitous Feature of Renal Cancer: Implications for Tumour Immune Evasion This is a repository copy of Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/158462/ Version: Accepted Version Article: Hornigold, N, Dunn, KR, Craven, RA et al. (22 more authors) (2020) Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion. British Journal of Cancer. ISSN 0007-0920 https://doi.org/10.1038/s41416-020-0874-y © The Author(s), under exclusive licence to Cancer Research UK 2020. This is an author produced version of an article published in British Journal of Cancer. Uploaded in accordance with the publisher's self-archiving policy. Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ 1 Dysregulation at multiple points of the kynurenine pathway is a 2 ubiquitous feature of renal cancer: implications for tumour 3 immune evasion 4 Nick Hornigold*1, Karen R Dunn*1, Rachel A Craven*1, Alexandre Zougman1, Sebastian 5 Trainor1, Rebecca Shreeve1, Joanne Brown1, Helen Sewell1, Michael Shires2, Margaret 6 Knowles3, Tsutomu Fukuwatari4, Eamonn R Maher5, Julie Burns3, Selina Bhattarai6, Mini 7 Menon6, Alvis Brazma7, Ghislaine Scelo8, Lara Feulner9, Yasser Riazalhosseini9, Mark 8 Lathrop9, Adrian Harris10, Peter J Selby1, Rosamonde E Banks1¡, Naveen S Vasudev1¡ 9 *these authors contributed equally to this work 10 ¡equal senior authors 11 1Clinical and Biomedical Proteomics Group, University of Leeds, St. James's University 12 Hospital, Beckett Street, Leeds LS9 7TF, UK; 2Leeds Institute of Medical Research at St 13 James’s, University of Leeds, St. James's University Hospital, Beckett Street, Leeds LS9 14 7TF, UK; 3Molecular Genetics Group, University of Leeds, St. James's University 15 Hospital, Beckett Street, Leeds LS9 7TF; 4Department of Nutrition, The University of Shiga 16 Prefecture, 2500 Hassaka, Hikone 5228533, Japan; 5Department of Medical Genetics, 17 University of Cambridge and NIHR Cambridge Biomedical Research Centre, and Cancer 18 Research UK Cambridge Centre, Cambridge Biomedical Campus, Cambridge CB2 0QQ, 19 UK; 6Department of Pathology, St James’s University Hospital, Beckett Street, Leeds LS9 20 7TF UK; 7European Molecular Biology Laboratory, European Bioinformatics Institute, 8 21 EMBL-EBI, Wellcome Trust Genome Campus, Hinxton CB10 1SD, UK;. International 22 Agency for Research on Cancer (IARC), Genetic Epidemiology Group, 150 cours Albert 23 Thomas, 69372, Lyon, France; 9McGill University and Genome Quebec Innovation 24 Centre, 740 Doctor Penfield Avenue, Montreal, QC, H3A 0G1, Canada;10Cancer 25 Research UK Clinical Centre, Weatherall Institute of Molecular Medicine, John Radcliffe 26 Hospital, Headington, Oxford OX3 9DS, UK 27 28 29 Corresponding author: Dr N Vasudev, St. James's University Hospital, Beckett Street, 30 Leeds LS9 7TF, UK. Tel: +44 113 2067680; Fax: +44 113 2429886; e-mail: 31 [email protected] 32 33 Running Title: Dysregulation of kynurenine pathway in RCC 34 Keywords: IDO1; kynurenine pathway; proteomics; QPRT; renal cell carcinoma 35 36 37 38 39 40 41 42 43 1 44 Abstract 45 46 Background: Indoleamine 2,3-dioxygenase (IDO), the first step in the kynurenine 47 pathway (KP), is upregulated in some cancers and represents an attractive therapeutic 48 target given its role in tumour immune evasion. However, the recent failure of an IDO 49 inhibitor in a late phase trial raises questions about this strategy. 50 Methods: Matched renal cell carcinoma (RCC) and normal kidney tissues were subject 51 to proteomic profiling. Tissue immunohistochemistry and gene expression data were used 52 to validate findings. Phenotypic effects of loss/gain of expression were examined in vitro. 53 Results: Quinolate phosphoribosyltransferase (QPRT), the final and rate-limiting enzyme 54 in the KP, was identified as being down-regulated in RCC. Loss of QPRT expression led 55 to increased potential for anchorage-independent growth. Gene expression, mass 56 spectrometry (clear cell and chromophobe RCC) and tissue immunohistochemistry (clear 57 cell, papillary and chromophobe), confirmed loss or decreased expression of QPRT, and 58 showed down-regulation of other KP enzymes including kynurenine 3-monoxygenase 59 (KMO) and 3-hydroxyanthranilate-3,4-dioxygenase (HAAO), with a concomitant 60 maintenance or up-regulation of nicotinamide phosphoribosyltransferase (NAMPT), the 61 key enzyme in the NAD+ salvage pathway. 62 Conclusions: Widespread dysregulation of the KP is common in RCC and is likely to 63 contribute to tumour immune evasion, carrying implications for effective therapeutic 64 targeting of this critical pathway 65 66 67 68 69 70 71 72 73 2 74 Introduction 75 Renal cancer is one of the ten most common adult cancers, accounting for over 100,000 76 deaths worldwide each year.1 It is also a cancer with one of the highest projected 77 increases in incidence over the next two decades.2 Almost 90% of these cancers arise 78 within the renal parenchyma and are termed renal cell carcinomas (RCCs). The most 79 common (75%) histological subtype is clear cell RCC (conventional) (ccRCC), which are 80 characterised by loss of the VHL tumour suppressor gene, followed by papillary (10-15%) 81 and chromophobe (5%) RCC. Each is considered to arise from distinct parts of the human 82 nephron, are genetically distinct3 and vary considerably in their clinical behaviour. 83 Treatment options for patients with RCC have burgeoned in recent years but, despite this, 84 it is a cancer that remains incurable for most patients with advanced disease. As in a 85 number of other tumour types, immunotherapy, in the form of checkpoint inhibitors (CPI), 86 has come to the forefront of patient treatment, both in the first- and second-line settings. 87 However, whilst some patients are observed to have deep and durable responses to these 88 agents, many patients fail to respond.4 It appears, therefore, that alone, CPI are not always 89 sufficient to overcome immune evasion and immune tolerance by tumours. Hence, 90 increasing attention is being focused on combining these drugs with other immune- 91 modifying targeted agents.5 92 Alterations in cellular metabolism are a hallmark of cancer,6 most notably perhaps the 93 ‘Warburg effect’, that describes the increased rate of glycolysis with reduced oxidative 94 phosphorylation characteristic of tumours.7 We were amongst the first to demonstrate this 95 comprehensively in renal cancers, using a proteomic approach, showing an up-regulation 96 in the majority of proteins in the glycolytic pathway and a parallel downregulation of 97 mitochondrial enzymes in comparison to normal renal tissues,8 highlighting novel 98 opportunities for therapeutic targeting.9 99 More recently, alteration in the metabolism of the essential amino acid tryptophan in 100 cancer, through the kynurenine pathway, has come to wide attention as a mechanism by 3 101 which tumours may escape immune control and promote disease progression. The 102 enzymes indoleamine 2,3-dioxygenase (IDO1, IDO2) and tryptophan 2,3-dioxygenase 103 (TDO) initiate the first steps in the kynurenine pathway, converting tryptophan to 104 kynurenine, with the TDO-dependent pathway in the liver normally accounting for the 105 majority of tryptophan metabolism and IDO-mediated metabolism predominantly 106 occurring secondary to inflammation and cytokine-induced upregulation.10 In normal 107 physiology, IDO plays an important role in tolerance to non-self antigens, for example fetal 108 antigens, where such immune non-responsiveness may be important.11,12 Up-regulation 109 of IDO leads to tryptophan depletion and kynurenine accumulation, which appear to work 110 in concert to mediate immunosuppression, via T-cell anergy and apoptosis and 111 suppressed T-cell differentiation.13 The harnessing of this phenomenon by tumours has 112 led to the development of inhibitors of IDO1 that have progressed to clinical trials in 113 combination with CPI. Despite much promise, initial results have, however, been 114 disappointing and the future of these agents currently remains uncertain.14,15 This may be 115 because of patient selection and lack of suitable profiling of immuno-regulating 116 metabolism, emphasising the need for a deeper understanding of these pathways. 117 Here, using a proteomic-based approach, we show that the kynurenine pathway is more 118 broadly disrupted than has been previously considered, extending beyond IDO1, that this 119 is a common event in RCC and is not just restricted to the clear cell histological subtype, 120 and suggests possible redundancy in the pathway within the tumour setting. Our findings 121 are of significance in terms of highlighting various aspects of this pathway for potential 122 therapeutic targeting, patient
Load more

Recommended publications
  • Integrated Analysis of Transcriptomic and Proteomic Analyses Reveals Different Metabolic Patterns in the Livers of Tibetan and Yorkshire Pigs
    Open Access Anim Biosci Vol. 34, No. 5:922-930 May 2021 https://doi.org/10.5713/ajas.20.0342 pISSN 2765-0189 eISSN 2765-0235 Integrated analysis of transcriptomic and proteomic analyses reveals different metabolic patterns in the livers of Tibetan and Yorkshire pigs Mengqi Duan1,a, Zhenmei Wang1,a, Xinying Guo1, Kejun Wang2, Siyuan Liu1, Bo Zhang3,*, and Peng Shang1,* * Corresponding Authors: Objective: Tibetan pigs, predominantly originating from the Tibetan Plateau, have been Bo Zhang Tel: +86-010-62734852, subjected to long-term natural selection in an extreme environment. To characterize the Fax: +86-010-62734852, metabolic adaptations to hypoxic conditions, transcriptomic and proteomic expression E-mail: [email protected] patterns in the livers of Tibetan and Yorkshire pigs were compared. Peng Shang Tel: +86-0894-5822924, Methods: RNA and protein were extracted from liver tissue of Tibetan and Yorkshire pigs Fax: +86-0894-5822924, (n = 3, each). Differentially expressed genes and proteins were subjected to gene ontology E-mail: [email protected] and Kyoto encyclopedia of genes and genomes functional enrichment analyses. 1 College of Animal Science, Tibet Agriculture Results: In the RNA-Seq and isobaric tags for relative and absolute quantitation analyses, a and Animal Husbandry University, Linzhi, total of 18,791 genes and 3,390 proteins were detected and compared. Of these, 273 and Xizang 86000, China 257 differentially expressed genes and proteins were identified. Evidence from functional 2 College of Animal Sciences and Veterinary Medicine, Henan Agricultural University, enrichment analysis showed that many genes were involved in metabolic processes. The Zhengzhou, Henan 450046, China combined transcriptomic and proteomic analyses revealed that small molecular biosynthesis, 3 National Engineering Laboratory for Animal metabolic processes, and organic hydroxyl compound metabolic processes were the major Breeding/Beijing Key Laboratory for Animal processes operating differently in the two breeds.
    [Show full text]
  • Deciphering Pre-Leukaemic Dysregulation Caused by Mutant C/Ebpα at the Level of the Single Cell
    Deciphering pre-leukaemic dysregulation caused by mutant C/EBPa at the level of the single cell Moosa Rashid Qureshi Department of Haematology University of Cambridge This dissertation is submitted for the degree of Doctor of Philosophy Queens’ College August 2019 DeClaration This thesis is the result of my own work and inCludes nothing whiCh is the outCome of work done in Collaboration exCept as deClared in the Acknowledgments and speCified in the text. It is not substantially the same as any that I have submitted, or, is being ConCurrently submitted for a degree or diploma or other qualifiCation at the University of Cambridge or any other University or similar institution exCept as deClared in the Acknowledgments and speCified in the text. I further state that no substantial part of my thesis has already been submitted, or, is being ConCurrently submitted for any suCh degree, diploma or other qualification at the University of Cambridge or any other University or similar institution exCept as deClared in the Acknowledgments and speCified in the text. It does not exCeed the prescribed word limit for the relevant Degree Committee Moosa Qureshi August 2019 I AbstraCt DeCiphering pre-leukaemic dysregulation Caused by mutant C/EBPa at the level of the single cell Moosa Rashid Qureshi C/EBPa is an ideal Candidate to explore pre-leukaemiC dysregulation of transCriptional networks beCause it is a signifiCant player in normal myelopoiesis, it interaCts with other transCription faCtors (TFs) in lineage speCification, and the CEBPA gene has been identified as an early mutation in acute myeloid leukaemia (AML). N321D is a mutation affeCting the leuCine zipper domain of C/EBPa whiCh has previously generated an aggressive AML phenotype in a mouse model.
    [Show full text]
  • The Interplay Between Cytokines and the Kynurenine Pathway in T Inflammation and Atherosclerosis ⁎ Roland Baumgartner , Maria J
    Cytokine 122 (2019) 154148 Contents lists available at ScienceDirect Cytokine journal homepage: www.elsevier.com/locate/cytokine The interplay between cytokines and the Kynurenine pathway in T inflammation and atherosclerosis ⁎ Roland Baumgartner , Maria J. Forteza, Daniel F.J. Ketelhuth Cardiovascular Medicine Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institute and Karolinska University Hospital, SE-17176 Stockholm, Sweden ARTICLE INFO ABSTRACT Keywords: The kynurenine pathway (KP) is the major metabolic route of tryptophan (Trp) metabolism. Indoleamine 2,3- Atherosclerosis dioxygenase (IDO1), the enzyme responsible for the first and rate-limiting step in the pathway, as well asother Inflammation enzymes in the pathway, have been shown to be highly regulated by cytokines. Hence, the KP has been im- Cytokine plicated in several pathologic conditions, including infectious diseases, psychiatric disorders, malignancies, and Kynurenine autoimmune and chronic inflammatory diseases. Additionally, recent studies have linked the KP with athero- Tryptophan sclerosis, suggesting that Trp metabolism could play an essential role in the maintenance of immune homeostasis in the vascular wall. This review summarizes experimental and clinical evidence of the interplay between cy- tokines and the KP and the potential role of the KP in cardiovascular diseases. 1. Introduction 2. The atherosclerotic process The kynurenine pathway (KP) is the major metabolic route of de- CVDs, which are largely due to atherosclerosis, are the
    [Show full text]
  • Multi-Omics Insights Into Functional Alterations of the Liver in Insulin-Deficient Diabetes Mellitus
    Accepted Manuscript Multi-omics insights into functional alterations of the liver in insulin-deficient diabetes mellitus Mattias Backman, Florian Flenkenthaler, Andreas Blutke, Maik Dahlhoff, Erik Ländström, Simone Renner, Julia Philippou-Massier, Stefan Krebs, Birgit Rathkolb, Cornelia Prehn, Michal Grzybek, Ünal Coskun, Michael Rothe, Jerzy Adamski, Martin Hrabĕ de Angelis, Rüdiger Wanke, Thomas Fröhlich, Georg J. Arnold, Helmut Blum, Eckhard Wolf PII: S2212-8778(19)30186-3 DOI: https://doi.org/10.1016/j.molmet.2019.05.011 Reference: MOLMET 818 To appear in: Molecular Metabolism Received Date: 28 February 2019 Revised Date: 20 May 2019 Accepted Date: 30 May 2019 Please cite this article as: Backman M, Flenkenthaler F, Blutke A, Dahlhoff M, Ländström E, Renner S, Philippou-Massier J, Krebs S, Rathkolb B, Prehn C, Grzybek M, Coskun Ü, Rothe M, Adamski J, de Angelis MH, Wanke R, Fröhlich T, Arnold GJ, Blum H, Wolf E, Multi-omics insights into functional alterations of the liver in insulin-deficient diabetes mellitus, Molecular Metabolism, https:// doi.org/10.1016/j.molmet.2019.05.011. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT 1 Multi-omics insights into functional alterations of the liver in 2 insulin-deficient diabetes mellitus 3 4 Mattias Backman,1,2,14 Florian Flenkenthaler,1,3,14 Andreas Blutke,4 Maik Dahlhoff,5 Erik 5 Ländström,1,2 Simone Renner,3,5,6 Julia Philippou-Massier,1,3 Stefan Krebs,1 Birgit 6 Rathkolb,3,5,7 Cornelia Prehn,8 Michal Grzybek,3,9 Ünal Coskun,3,9 Michael Rothe, 10 Jerzy 7 Adamski,8,11,12 Martin Hrab ĕ de Angelis,3,7,11 Rüdiger Wanke,13 Thomas Fröhlich,1 Georg J.
    [Show full text]
  • Genetic Analysis of Tryptophan Metabolism Genes in Sporadic Amyotrophic Lateral Sclerosis
    ORIGINAL RESEARCH published: 14 June 2021 doi: 10.3389/fimmu.2021.701550 Genetic Analysis of Tryptophan Metabolism Genes in Sporadic Amyotrophic Lateral Sclerosis Jennifer A. Fifita 1, Sandrine Chan Moi Fat 1, Emily P. McCann 1, Kelly L. Williams 1, Natalie A. Twine 1,2, Denis C. Bauer 2,3,4, Dominic B. Rowe 1,5, Roger Pamphlett 6,7,8, † † Matthew C. Kiernan 8,9, Vanessa X. Tan 1, Ian P. Blair 1* and Gilles J. Guillemin 1 1 Macquarie University Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia, 2 Australian e-Health Research Centre, Edited by: Commonwealth Scientific and Industrial Research Organization, Health & Biosecurity Flagship, Sydney, NSW, Australia, Sermin Genc, 3 Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Dokuz Eylul University, Turkey NSW, Australia, 4 Applied BioSciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, Australia, Reviewed by: 5 Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Zhang-Yu Zou, Australia, 6 Discipline of Pathology, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia, 7 Department Fujian Medical University Union of Neuropathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, 8 Brain and Mind Centre, University of Sydney, Hospital, China Sydney, NSW, Australia, 9 Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, NSW, Australia Nazli Ayse Basak, Koc¸ University, Turkey Claudia Figueroa-Romero, The essential amino acid tryptophan (TRP) is the initiating metabolite of the kynurenine University of Michigan, United States pathway (KP), which can be upregulated by inflammatory conditions in cells.
    [Show full text]
  • THESIS for DOCTORAL DEGREE (Ph.D.)
    From Department of Laboratory Medicine, Division of Pathology Karolinska Institutet, Stockholm, Sweden SELENIUM COMPOUNDS AS A NOVEL CLASS OF EXPERIMENTAL CANCER CHEMOTHERAPEUTICS Arun Kumar Selvam Stockholm 2021 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Universitetsservice US-AB, 2021 © Arun Kumar Selvam, 2021 ISBN 978-91-8016-136-7 Cover illustration: Selenium compounds from nutrient supplements to chemotherapeutic agents. Art by Sougat Misra. Selenium compounds as a novel class of experimental cancer chemotherapeutics THESIS FOR DOCTORAL DEGREE (Ph.D.) By Arun Kumar Selvam The thesis will be defended in public at 4X, Alfred Nobels Alle 8, level 4, Huddinge, 19th March 2021, 10.00AM Principal Supervisor: Opponent: Professor Mikael Björnstedt Professor Michael Jonathan Davies Karolinska Institutet University of Copenhagen Department of Laboratory Medicine Department of Biomedical Sciences Division of Pathology Examination Board: Professor Richard Palmqvist Co-supervisor(s): Umeå universitet Assistant Research Professor Sougat Misra Department of Medical Biosciences The Pennsylvania State University Department of Veterinary and Biomedical Professor Göran Andersson Sciences Karolinska Institutet Department of Laboratory Medicine Division of Pathology Professor Magnus Björkholm Karolinska Institutet Department of Medicine To my family and everyone who supported me 鎿쏁க்埁றள் (Thirukural) – 396 அ鎿காரம்/Chapter: கல்ힿ / Learning ததாட்டனைத் 鏂쟁ம் மணற்ககணி மாந்தர்க்埁க் கற்றனைத் 鏂쟁ம் அ잿ퟁ. Meaning: Water will flow from a well in the sand in proportion to the depth to which it is dug, and knowledge will flow from a person in proportion to his/her learning - Thiruvalluvar POPULAR SCIENCE SUMMARY OF THE THESIS Selenium is an essential micronutrient for human health, selenium deficiency or overdose leads to health problems, so optimal intake (50-200µg/day) is necessary to maintain proper health.
    [Show full text]
  • A Novel Mrna-Mediated and Microrna-Guided Approach to Specifically Eradicate Drug-Resistant Hepatocellular Carcinoma Cell Lines by Se-Methylselenocysteine
    antioxidants Article A Novel mRNA-Mediated and MicroRNA-Guided Approach to Specifically Eradicate Drug-Resistant Hepatocellular Carcinoma Cell Lines by Se-Methylselenocysteine Arun Kumar Selvam 1 , Rim Jawad 1,†, Roberto Gramignoli 1 , Adnane Achour 2 , Hugh Salter 1,3 and Mikael Björnstedt 1,* 1 Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Karolinska University Hospital, S-141 86 Stockholm, Sweden; [email protected] (A.K.S.); [email protected] (R.J.); [email protected] (R.G.); [email protected] (H.S.) 2 Science for Life Laboratory, Department of Medicine Solna, Karolinska Institute, & Division of Infectious Diseases, Karolinska University Hospital, SE-171 77 Solna, Sweden; [email protected] 3 Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA * Correspondence: [email protected] † Present address: Unit for Molecular Cell and Gene Therapy Science, Clinical Research Centre, Department of Laboratory Medicine Karolinska Institutet, SE-141 86 Stockholm, Sweden. Abstract: Despite progress in the treatment of non-visceral malignancies, the prognosis remains poor for malignancies of visceral organs and novel therapeutic approaches are urgently required. We evaluated a novel therapeutic regimen based on treatment with Se-methylselenocysteine (MSC) and Citation: Selvam, A.K.; Jawad, R.; concomitant tumor-specific induction of Kynurenine aminotransferase 1 (KYAT1) in hepatocellular Gramignoli, R.; Achour, A.; Salter, H.; carcinoma (HCC) cell lines, using either vector-based and/or lipid
    [Show full text]
  • SUPPLEMENTARY APPENDIX Long Non-Coding RNA NEAT1 Shows High Expression Unrelated to Molecular Features and Clinical Outcome in Multiple Myeloma
    SUPPLEMENTARY APPENDIX Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma Elisa Taiana, 1,2* Domenica Ronchetti, 1,2* Vanessa Favasuli, 1,2 Katia Todoerti, 1,2 Martina Manzoni, 1,2 Nicola Amodio, 3 Pierfrancesco Tassone, 3,4 Luca Agnelli 1,2 and Antonino Neri 1,2 1Department of Oncology and Hemato-oncology, University of Milan, Italy; 2Hematology, Fondazione Cà Granda IRCCS Policlinico, Milan, Italy; 3Depart - ment of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy and 4Sbarro Institute for Cancer Research and Molecu - lar Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA *ET and DR contributed equally to this work. Correspondence: [email protected] doi:10.3324/haematol.2018.201301 Supplementary Materials Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma Elisa Taiana,1,2* Domenica Ronchetti,1,2* Vanessa Favasuli,1,2 Katia Todoerti, 1,2 Martina Manzoni,1,2 Nicola Amodio,3 Pierfrancesco Tassone,3,4 Luca Agnelli, 1,2 Antonino Neri1,2 1Department of Oncology and Hemato-oncology, University of Milan, Italy 2Hematology, Fondazione Cà Granda IRCCS Policlinico, Milan, Italy 3Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy 4Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, US Corresponding author: Antonino Neri, MD, PhD Fax: +39 02-50320403 e-mail: [email protected] Supplementary Materials and Methods Samples We investigated a cohort of 50 MM patients representative of the major molecular characteristics of the disease, 9 primary PCLs (pPCL) and 6 secondary PCLs (sPCL) and four normal controls (purchased from Voden, Medical Instruments IT) (Table 1).
    [Show full text]
  • The Rtopper Package: Perform Run Gene Set Enrichment Across Genomic Platforms
    The RTopper package: perform run Gene Set Enrichment across genomic platforms Luigi Marchionni Department of Oncology Johns Hopkins University email: [email protected] May 19, 2021 Contents 1 Overview 1 2 RTopper data structure 2 2.1 Creation of Functional Gene Sets . .4 3 Data analysis with RTopper 8 3.1 Integrated Gene-to-Phenotype score computation . 10 3.2 Separate Gene-to-Phenotype score computation . 10 3.3 Gene Set Enrichment using integrated and separate score . 10 3.4 INTEGRATION + GSE . 11 3.4.1 One-sided Wilcoxon rank-sum test using absolute ranking statistics . 12 3.4.2 One-sided Wilcoxon rank-sum test using signed ranking statistics . 12 3.4.3 Performing a simulation-based GSE test . 12 3.4.4 Passing alternative enrichment functions to runBatchGSE ........... 13 3.5 GSE + INTEGRATION . 14 3.6 Multiple testing correction . 16 4 System Information 17 5 References 19 1 Overview Gene Set Enrichment (GSE) analysis has been widely use to assist the interpretation of gene expression data. We propose here to apply GSE for the integration of genomic data obtained from distinct analytical platform. In the present implementation of the RTopper GSE analysis is performed using the geneSetTest function from the limma package [6, 5, 7]. This function enables testing the hypothesis that a specific set of genes (a Functional Gene Set, FGS) is more highly ranked on a given statistics. In 1 particular this functions computes a p-value for each FGS by one or two-sided Wilcoxon rank-sum test. Alternative user-defined functions can also be used.
    [Show full text]
  • Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma
    Published OnlineFirst April 24, 2018; DOI: 10.1158/1078-0432.CCR-18-0041 Cancer Therapy: Preclinical Clinical Cancer Research Tryptophan Metabolism Contributes to Radiation- Induced Immune Checkpoint Reactivation in Glioblastoma Pravin Kesarwani1, Antony Prabhu1, Shiva Kant1, Praveen Kumar2, Stewart F. Graham2, Katie L. Buelow1, George D. Wilson1, C. Ryan Miller3, and Prakash Chinnaiyan1,4 Abstract Purpose: Immune checkpoint inhibitors designed to revert tryptophan metabolism as a metabolic node specifictothe tumor-induced immunosuppression have emerged as potent mesenchymal and classical subtypes of glioblastoma. GDC- anticancer therapies. Tryptophan metabolism represents an 0919 demonstrated potent inhibition of this node and effec- immune checkpoint, and targeting this pathway's rate-limiting tively crossed the blood–brain barrier. Although GDC-0919 as enzyme IDO1 is actively being investigated clinically. Here, we a single agent did not demonstrate antitumor activity, it had a studied the intermediary metabolism of tryptophan metabolism strong potential for enhancing RT response in glioblastoma, in glioblastoma and evaluated the activity of the IDO1 inhibitor which was further augmented with a hypofractionated regimen. GDC-0919, both alone and in combination with radiation (RT). RT response in glioblastoma involves immune stimulation, Experimental Design: LC/GC-MS and expression profiling was reflected by increases in activated and cytotoxic T cells, which performed for metabolomic and genomic analyses of patient- was balanced by immune checkpoint reactivation, reflected by derived glioma. Immunocompetent mice were injected orthoto- an increase in IDO1 expression and regulatory T cells (Treg). pically with genetically engineered murine glioma cells and GDC-0919 mitigated RT-induced Tregs and enhanced T-cell treated with GDC-0919 alone or combined with RT.
    [Show full text]
  • Tryptophan Metabolism Contributes to Radiation
    Published OnlineFirst April 24, 2018; DOI: 10.1158/1078-0432.CCR-18-0041 Translational Cancer Mechanisms and Therapy Clinical Cancer Research Tryptophan Metabolism Contributes to Radiation- Induced Immune Checkpoint Reactivation in Glioblastoma Pravin Kesarwani1, Antony Prabhu1, Shiva Kant1, Praveen Kumar2, Stewart F. Graham2, Katie L. Buelow1, George D. Wilson1, C. Ryan Miller3, and Prakash Chinnaiyan1,4 Abstract Purpose: Immune checkpoint inhibitors designed to revert aberrant tryptophan metabolism as a metabolic node spe- tumor-induced immunosuppression have emerged as potent cific to the mesenchymal and classical subtypes of glioblas- anticancer therapies. Tryptophan metabolism represents an toma. GDC-0919 demonstrated potent inhibition of this immune checkpoint, and targeting this pathway's rate-limiting node and effectively crossed the blood–brain barrier. enzyme IDO1 is actively being investigated clinically. Here, we Although GDC-0919 as a single agent did not demonstrate studied the intermediary metabolism of tryptophan metabo- antitumor activity, it had a strong potential for enhancing lism in glioblastoma and evaluated the activity of the IDO1 RT response in glioblastoma, which was further augmented inhibitor GDC-0919, both alone and in combination with with a hypofractionated regimen. RT response in glioblas- radiation (RT). toma involves immune stimulation, reflected by increases in Experimental Design: LC/GC-MS and expression profiling activated and cytotoxic T cells, which was balanced by was performed for metabolomic and genomic analyses of immune checkpoint reactivation, reflected by an increase patient-derived glioma. Immunocompetent mice were in IDO1 expression and regulatory T cells (Treg). GDC-0919 injected orthotopically with genetically engineered murine mitigated RT-induced Tregs and enhanced T-cell activation.
    [Show full text]
  • Transcriptomic Analyses of Gastrulation-Stage Mouse Embryos with Differential Susceptibility to Alcohol Karen E
    © 2021. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2021) 14, dmm049012. doi:10.1242/dmm.049012 RESEARCH ARTICLE Transcriptomic analyses of gastrulation-stage mouse embryos with differential susceptibility to alcohol Karen E. Boschen1, Travis S. Ptacek2,3, Matthew E. Berginski4, Jeremy M. Simon2,3,5 and Scott E. Parnell1,6,7,* ABSTRACT and central nervous system (Cook et al., 1987). Specifically, Genetics are a known contributor to differences in alcohol sensitivity in prenatal alcohol exposure (PAE) during gastrulation [third humans with fetal alcohol spectrum disorders (FASDs) and in animal week of human pregnancy; embryonic day (E)7 in mice] results in models. Our study profiled gene expression in gastrulation-stage the craniofacial malformations characteristic of fetal alcohol embryos from two commonly used, genetically similar mouse syndrome (FAS), including a thin upper lip, smooth philtrum, substrains, C57BL/6J (6J) and C57BL/6NHsd (6N), that differ in reduced head circumference and small eyes (Cook et al., 1987). In alcohol sensitivity. First, we established normal gene expression addition, gastrulation-stage PAE is associated with loss of midline patterns at three finely resolved time points during gastrulation and brain tissue, including agenesis of the corpus callosum and developed a web-based interactive tool. Baseline transcriptional holoprosencephaly (Higashiyama et al., 2007; Godin et al., 2010), differences across strains were associated with immune signaling. disrupted morphogenic signaling (Zhang et al., 2014; Kietzman et al., Second, we examined the gene networks impacted by alcohol 2014; Aoto et al., 2008) and widespread apoptosis (Dunty et al., in each strain. Alcohol caused a more pronounced transcriptional 2001).
    [Show full text]